Sagent Pharmaceuticals Company Profile (NASDAQ:SGNT)

About Sagent Pharmaceuticals (NASDAQ:SGNT)

Sagent Pharmaceuticals logoSagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SGNT
  • CUSIP: 78669210
  • Web:
Average Prices:
  • 50 Day Moving Avg: $21.72
  • 200 Day Moving Avg: $15.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 29.77
  • P/E Growth: 0.00
  • Net Margins: -0.72%
  • Return on Equity: -0.81%
  • Return on Assets: -0.59%
  • Beta: 1.66

Frequently Asked Questions for Sagent Pharmaceuticals (NASDAQ:SGNT)

What is Sagent Pharmaceuticals' stock symbol?

Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."

How were Sagent Pharmaceuticals' earnings last quarter?

Sagent Pharmaceuticals Inc (NASDAQ:SGNT) released its quarterly earnings results on Tuesday, May, 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.01 by $0.16. The business earned $67.30 million during the quarter, compared to the consensus estimate of $74.30 million. Sagent Pharmaceuticals had a negative net margin of 0.72% and a negative return on equity of 0.81%. The business's quarterly revenue was down 17.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.04 earnings per share. View Sagent Pharmaceuticals' Earnings History.

Who are some of Sagent Pharmaceuticals' key competitors?

How do I buy Sagent Pharmaceuticals stock?

Shares of Sagent Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sagent Pharmaceuticals' stock price today?

One share of Sagent Pharmaceuticals stock can currently be purchased for approximately $21.73.

MarketBeat Community Rating for Sagent Pharmaceuticals (NASDAQ SGNT)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Price Target History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2016Deutsche Bank AGDowngradeBuy -> HoldN/AView Rating Details
7/12/2016Raymond James Financial, Inc.DowngradeBuy -> Market PerformN/AView Rating Details
7/11/2016Royal Bank Of CanadaDowngradeOutperform -> HoldN/AView Rating Details
7/11/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$22.00 -> $21.75N/AView Rating Details
6/17/2016Jefferies Group LLCReiterated RatingHold$13.00 -> $15.00N/AView Rating Details
6/1/2016J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
5/9/2016Bank of America CorporationReiterated RatingHold$13.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Earnings by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Earnings History by Quarter for Sagent Pharmaceuticals (NASDAQ SGNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2016Q1$0.01($0.15)$74.30 million$67.30 millionViewN/AView Earnings Details
2/16/2016Q415($0.02)($0.55)$78.13 million$83.10 millionViewListenView Earnings Details
11/3/2015Q315($0.07)$0.01$73.84 million$75.20 millionViewN/AView Earnings Details
8/4/2015Q215$0.05($0.01)$83.28 million$77.30 millionViewN/AView Earnings Details
5/5/2015Q115$0.04$0.04$80.63 million$82.60 millionViewN/AView Earnings Details
2/19/2015Q414$0.01$0.91$76.20 million$84.40 millionViewN/AView Earnings Details
11/4/2014Q314($0.04)$0.08$64.01 million$65.40 millionViewN/AView Earnings Details
7/30/2014Q214($0.01)$0.09$67.14 million$69.20 millionViewListenView Earnings Details
5/6/2014Q114($0.02)$0.16$65.66 million$70.90 millionViewListenView Earnings Details
2/11/2014Q4($0.01)$0.11$60.25 million$64.10 millionViewListenView Earnings Details
11/5/2013($0.03)$0.10ViewN/AView Earnings Details
8/6/2013Q2 2013$0.46$59.27 million$59.60 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)$0.34$55.31 million$60.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.20)($0.13)$48.60 million$49.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)
Current Year EPS Consensus Estimate: $0.24 EPS
Next Year EPS Consensus Estimate: $0.73 EPS


Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Institutional Ownership by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/21/2016Ventures Fund V L.P. VivoMajor ShareholderSell2,005$13.55$27,167.75View SEC Filing  
11/4/2015Ventures Fund V L.P. VivoMajor ShareholderSell603,177$15.72$9,481,942.44View SEC Filing  
11/3/2015Vivo Ventures Vi, LlcMajor ShareholderSell67,283$16.32$1,098,058.56View SEC Filing  
11/2/2015Vivo Ventures Vi, LlcMajor ShareholderSell93,523$16.87$1,577,733.01View SEC Filing  
1/27/2015Morgan Stanley Investment ManaMajor ShareholderSell78,041$26.16$2,041,552.56View SEC Filing  
1/23/2015Morgan Stanley Investment ManaMajor ShareholderSell211,883$25.61$5,426,323.63View SEC Filing  
1/21/2015Morgan Stanley Investment ManaMajor ShareholderSell69,316$25.23$1,748,842.68View SEC Filing  
1/16/2015Morgan Stanley Investment ManaMajor ShareholderSell125,000$25.16$3,145,000.00View SEC Filing  
1/14/2015Morgan Stanley Investment ManaMajor ShareholderSell100,000$25.51$2,551,000.00View SEC Filing  
10/8/2014Robert J FlanaganDirectorSell16,000$31.56$504,960.00View SEC Filing  
10/7/2014Robert J FlanaganDirectorSell8,000$31.15$249,200.00View SEC Filing  
9/25/2014Robert J FlanaganDirectorSell16,000$30.01$480,160.00View SEC Filing  
9/24/2014Robert J FlanaganDirectorSell8,000$30.30$242,400.00View SEC Filing  
9/12/2014Robert J FlanaganDirectorSell16,000$28.30$452,800.00View SEC Filing  
9/11/2014Robert J FlanaganDirectorSell8,000$28.35$226,800.00View SEC Filing  
8/28/2014Robert J FlanaganDirectorSell16,000$27.19$435,040.00View SEC Filing  
8/27/2014Robert J FlanaganDirectorSell8,000$27.30$218,400.00View SEC Filing  
8/12/2014Robert J FlanaganDirectorSell16,000$24.39$390,240.00View SEC Filing  
7/31/2014Robert J FlanaganDirectorSell16,000$25.60$409,600.00View SEC Filing  
7/18/2014Robert J FlanaganDirectorSell16,000$26.18$418,880.00View SEC Filing  
7/2/2014Robert J FlanaganDirectorSell16,000$26.51$424,160.00View SEC Filing  
6/18/2014Robert J FlanaganDirectorSell16,000$23.37$373,920.00View SEC Filing  
6/4/2014Robert J FlanaganDirectorSell16,000$22.17$354,720.00View SEC Filing  
5/22/2014Robert FlanaganDirectorSell8,000$22.02$176,160.00View SEC Filing  
2/27/2014Michael LogerfoInsiderSell2,021$21.43$43,310.03View SEC Filing  
10/3/2013Morgan Stanley Investment Manamajor shareholderSell47,826$20.27$969,433.02View SEC Filing  
9/26/2013Morgan Stanley Investment Manamajor shareholderSell67,965$20.37$1,384,447.05View SEC Filing  
9/25/2013Morgan Stanley Investment Manamajor shareholderSell48,124$21.30$1,025,041.20View SEC Filing  
9/23/2013Morgan Stanley Investment Manamajor shareholderSell119,557$21.83$2,609,929.31View SEC Filing  
9/19/2013Morgan Stanley Investment Manamajor shareholderSell88,885$22.53$2,002,579.05View SEC Filing  
9/16/2013Frank KungDirectorSell1,161,717$21.25$24,686,486.25View SEC Filing  
9/16/2013Jeffrey YordonCEOSell85,813$20.03$1,718,834.39View SEC Filing  
9/16/2013Vivo Ventures Vi, Llcmajor shareholderSell622,700$21.25$13,232,375.00View SEC Filing  
8/12/2013Lorin DrakeVPSell1,000$23.69$23,690.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sagent Pharmaceuticals (NASDAQ:SGNT)
Latest Headlines for Sagent Pharmaceuticals (NASDAQ:SGNT)



Sagent Pharmaceuticals (SGNT) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.